Studies have shown that anti-IL-6 therapy could not directly affect the effect of ICIs but could enhance their anticancer function, which may be an option for managing immune-related adverse events (irAEs) and a therapeutic target for treating NSCLC (65). This evidence concerns the gene IL6 and non-small cell lung carcinoma.